Related Experiment Video
Updated: Aug 17, 2025
03:32
Single Incision Plus One Port Laparoscopic Proximal Gastrectomy with Double Channel Anastomosis for Gastric Cancer Treatment
Published on: December 27, 2024
873
Conversion surgery for stage IV gastric cancer: a multicenter retrospective study
Yosuke Kano1, Hiroshi Ichikawa2, Takaaki Hanyu1,3
1Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.
BMC Surgery
|December 14, 2022
Summary
Conversion surgery (CS) offers a survival benefit for selected stage IV gastric cancer (GC) patients. Achieving R0 resection and having initially resectable disease are key factors for improved outcomes in GC patients undergoing CS.
Area of Science:
- Surgical Oncology
- Gastrointestinal Oncology
- Cancer Treatment
Background:
- Systemic chemotherapy advancements enable conversion surgery (CS) for stage IV gastric cancer (GC).
- Evaluating long-term outcomes and prognostic factors for CS in stage IV GC is crucial.
Purpose of the Study:
- To assess the long-term results of conversion surgery (CS) in stage IV gastric cancer (GC).
- To identify prognostic factors influencing the success of CS in stage IV GC patients.
Main Methods:
- Retrospective review of clinicopathological data and prognosis for 79 stage IV GC patients who underwent CS.
- Analysis focused on R0 resection achievement and patient outcomes across different disease statuses.
Main Results:
- R0 resection was achieved in 79.7% of patients.
- Initially resectable (IR) disease and R0 resection were significant independent prognostic factors for overall survival (OS).
- Patients with peritoneal dissemination undergoing R0 resection had significantly better 3-year OS (65.5%) than those with R1/2 resection (23.1%).
Conclusions:
- Conversion surgery (CS) is a viable treatment option for carefully selected stage IV GC patients.
- Patients with initially resectable disease and those achieving R0 resection may experience improved survival following CS.
